Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Patients with advanced chronic kidney disease (CKD) face significantly worse outcomes when treated with immune checkpoint inhibitors (ICIs) for genitourinary cancers. A large study found nearly 45% of advanced CKD patients died within 2 years of ICI treatment, compared to 35.5% with early CKD. Experts say CKD shouldn't automatically rule out ICI use, but close monitoring is essential.
Immune checkpoint inhibitors (ICIs) are a cornerstone of treatment for genitourinary cancers like renal cell carcinoma (RCC) and urothelial carcinoma — but a new study suggests patients with advanced chronic kidney disease (CKD) face a notably rougher road. Researchers analyzed data from over 4,300 propensity-score matched patients across 63 U.S. centers and found that advanced CKD was linked to significantly worse survival and higher rates of immune-related side effects compared to early CKD.
Published in Cancer Immunology and Immunotherapy, the study points to uremia's ability to impair immune cell function as a likely culprit, alongside the broader burden of cardiovascular disease, malnutrition, and reduced physiologic reserve that comes with advanced CKD — factors that may blunt the very immune response ICIs are designed to amplify.
By the Numbers:
Why it matters: Advanced CKD is common among cancer patients, yet this population is often underrepresented in clinical trials. These findings give clinicians critical real-world data to guide treatment decisions, emphasizing the need for close renal monitoring and multidisciplinary care — not blanket exclusion from ICI therapy.
